Effect of long-term treatment with recombinant human growth hormone on erythropoietin secretion in an anemic patient with panhypopituitarism

2000 ◽  
Vol 23 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Motoi Sohmiya ◽  
Y. Kato
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Anemic Patient ◽  
Long Term Treatment

Predicting the Response of Growth Hormone-Deficient Children to Long Term Treatment with Human Growth Hormone*

1979 ◽  
Vol 48 (3) ◽  
pp. 472-477 ◽  
Author(s):  
DANIEL RUDMAN ◽  
MICHAEL H. KUTNER ◽  
MARTIN A. GOLDSMITH ◽  
R.DWAIN BLACKSTON
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Long Term Treatment

Long-term treatment of hypopituitary and of achondroplastic dwarfism with human growth hormone

Metabolism ◽  
1964 ◽  
Vol 13 (2) ◽  
pp. 152-160 ◽  
Author(s):  
Herbert Gershberg ◽  
Silvia Mari ◽  
Mildred Hulse ◽  
Henry St. Paul
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Long Term Treatment

SULPHATION FACTOR ACTIVITY AND GROWTH RATE DURING LONG-TERM TREATMENT OF PATIENTS WITH PITUITARY DWARFISM WITH HUMAN GROWTH HORMONE

1972 ◽  
Vol 69 (3) ◽  
pp. 417-433 ◽  
Author(s):  
Kerstin Hall ◽  
Patrick Olin
Keyword(s):  
Growth Hormone ◽  
Growth Rate ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Factor Activity ◽  
Duration Of Treatment ◽  
Pituitary Dwarfism ◽  
Long Term Treatment

ABSTRACT Twenty patients with pituitary dwarfism were treated for nine months to 2½ years with human growth hormone (HGH) prepared according to Roos et al. (1963). Eleven of them had previously been given other HGH preparations for one to five years. During the first two years of treatment with HGH in a dose of 0.2 mg (0.4 IU) and 0.3 mg (0.6 IU) per kg body weight per week, the increase in growth rate was two- to threefold, and three- to fivefold, respectively. Long-termed treatment with HGH was accompanied by a decreasing ability of the hormone to stimulate growth. Cortisone acetate, in replacement doses, had no influence on this growth rate. During the present study only one of the 20 patients developed antibodies to HGH. The levels of sulphation factor (SF) activity in serum were low before treatment and increased significantly during treatment with HGH. There was a linear relationship between the SF activity in the serum and the slope of the growth carves. Both increased with the dose of HGH administered but decreased with duration of treatment.

Long-term effects of recombinant human growth hormone treatment on skeletal maturation and growth in female rhesus monkeys with normal pituitary function

1991 ◽  
Vol 130 (3) ◽  
pp. 435-441 ◽  
Author(s):  
M. E. Wilson ◽  
J. M. Tanner
Keyword(s):  
Growth Hormone ◽  
Rhesus Monkeys ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Term Treatment ◽  
Crown Rump Length ◽  
Long Term Treatment ◽  
Female Rhesus ◽  
Tibia Length

ABSTRACT Female rhesus monkeys (n = 5), having normal pituitary function, were treated for 50 months with recombinant human growth hormone (rhGH; 250 μg/kg) 3 days/week (Monday, Wednesday and Friday) and rates of growth were compared with a group of age-matched untreated females (n = 6). Treatment was initiated at 20 months of age, approximately 10 months before the expected age of menarche. Long-term treatment with rhGH accelerated bone maturation and increased the velocity of increase in crown–rump length, tibia length and body weight. The period of acceleration occurred coincident with the occurrence of spontaneous puberty. Body measurements remained larger in the treated females until growth ceased. Long-term rhGH treatment increased final adult crown–rump length by some 3%, with a slight increase in tibia length and body weight, without having any untoward effects on reproductive capacity or health. One treated animal exhibited higher estimates of antibodies to rhGH throughout the study period, and this female also had a smaller increment in crown–rump length than the other treated females. These data suggest that long-term treatment of normal-pituitary females with rhGH augments crown–rump growth without any untoward effects of health. Journal of Endocrinology (1991) 130, 435–441

SERUM LEVELS OF SOMATOMEDIN A AND GROWTH DURING LONG-TERM TREATMENT OF PATIENTS WITH PITUITARY DWARFISM WITH HUMAN GROWTH HORMONE

1979 ◽  
Vol 92 (3) ◽  
pp. 385-397 ◽  
Author(s):  
Kazue Takano ◽  
Naomi Hizuka ◽  
Kazuo Shizume ◽  
Yoko Hasumi
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Human Growth ◽  
Bone Age ◽  
Serum Levels ◽  
Term Treatment ◽  
Duration Of Treatment ◽  
Pituitary Dwarfism ◽  
Long Term Treatment

ABSTRACT Eighteen patients with pituitary dwarfism were treated for 1 7/12 to 6 years with human growth hormone (hGH) at a dose of 0.19–0.62 unit (U) per kg of body weight per week. The mean increment in height was 2.0 ± 0.4 and 8.8 ± 0.5 cm/year before and the first year after treatment of hGH, respectively. A significant positive correlation was observed between serum levels of somatomedin A and growth rate, especially in children with bone age below 10 and a duration of treatment of less than one year (r = 0.66, P < 0.005). Long-term treatment with hGH was accompanied by a decreasing response. However, the serum levels of somatomedin A did not decrease significantly. Therefore, decreased growth increment in these situations was not due to decreased serum levels of somatomedin A.

Sign in / Sign up

Export Citation Format

Share Document